Vittorio de Franciscis - Search Results

Year	Number of Results
2002	2
2003	1
2004	3
2005	2
2006	3
2007	2
2008	1
2009	5
2010	1
2011	5
2012	2
2013	2
2014	4
2015	5
2016	10
2017	6
2018	6
2019	2
2020	2
2021	3

1

Retraction: Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase.

Cerchia L, Ducongé F, Pestourie C, Boulay J, Aissouni Y, Gombert K, Tavitian B, de Franciscis V, Libri D. Cerchia L, et al. Among authors: de franciscis v. PLoS Biol. 2015 Jul 17;13(7):e1002215. doi: 10.1371/journal.pbio.1002215. eCollection 2015 Jul. PLoS Biol. 2015. PMID: 26186737 Free PMC article. No abstract available.

2

Nucleic acids delivering nucleic acids.

Catuogno S, Esposito CL, Condorelli G, de Franciscis V. Catuogno S, et al. Among authors: de franciscis v. Adv Drug Deliv Rev. 2018 Sep;134:79-93. doi: 10.1016/j.addr.2018.04.006. Epub 2018 Apr 6. Adv Drug Deliv Rev. 2018. PMID: 29630917 Review.

3

Challenging cancer targets for aptamer delivery.

de Franciscis V. de Franciscis V. Biochimie. 2018 Feb;145:45-52. doi: 10.1016/j.biochi.2017.09.014. Epub 2017 Sep 28. Biochimie. 2018. PMID: 28962871 Review.

4

Axl-148b chimeric aptamers inhibit breast cancer and melanoma progression.

Quirico L, Orso F, Esposito CL, Bertone S, Coppo R, Conti L, Catuogno S, Cavallo F, de Franciscis V, Taverna D. Quirico L, et al. Among authors: de franciscis v. Int J Biol Sci. 2020 Feb 10;16(7):1238-1251. doi: 10.7150/ijbs.39768. eCollection 2020. Int J Biol Sci. 2020. PMID: 32174798 Free PMC article.

5

Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives.

Esposito CL, Catuogno S, Condorelli G, Ungaro P, de Franciscis V. Esposito CL, et al. Among authors: de franciscis v. Genes (Basel). 2018 Oct 31;9(11):529. doi: 10.3390/genes9110529. Genes (Basel). 2018. PMID: 30384431 Free PMC article. Review.

6

Aptamer-Mediated Targeted Delivery of Therapeutics: An Update.

Catuogno S, Esposito CL, de Franciscis V. Catuogno S, et al. Among authors: de franciscis v. Pharmaceuticals (Basel). 2016 Nov 3;9(4):69. doi: 10.3390/ph9040069. Pharmaceuticals (Basel). 2016. PMID: 27827876 Free PMC article. Review.

7

Combined Targeting of Glioblastoma Stem-Like Cells by Neutralizing RNA-Bio-Drugs for STAT3.

Esposito CL, Nuzzo S, Ibba ML, Ricci-Vitiani L, Pallini R, Condorelli G, Catuogno S, de Franciscis V. Esposito CL, et al. Among authors: de franciscis v. Cancers (Basel). 2020 May 31;12(6):1434. doi: 10.3390/cancers12061434. Cancers (Basel). 2020. PMID: 32486489 Free PMC article.

8

Cell-specific aptamers for targeted therapies.

Cerchia L, Giangrande PH, McNamara JO, de Franciscis V. Cerchia L, et al. Among authors: de franciscis v. Methods Mol Biol. 2009;535:59-78. doi: 10.1007/978-1-59745-557-2_5. Methods Mol Biol. 2009. PMID: 19377980 Free PMC article. Review.

9

Nucleic Acid Aptamers Targeting Epigenetic Regulators: An Innovative Therapeutic Option.

Catuogno S, Esposito CL, Ungaro P, de Franciscis V. Catuogno S, et al. Among authors: de franciscis v. Pharmaceuticals (Basel). 2018 Aug 24;11(3):79. doi: 10.3390/ph11030079. Pharmaceuticals (Basel). 2018. PMID: 30149585 Free PMC article. Review.

10

An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery.

Catuogno S, Di Martino MT, Nuzzo S, Esposito CL, Tassone P, de Franciscis V. Catuogno S, et al. Among authors: de franciscis v. Mol Ther Nucleic Acids. 2019 Dec 6;18:981-990. doi: 10.1016/j.omtn.2019.10.021. Epub 2019 Oct 28. Mol Ther Nucleic Acids. 2019. PMID: 31778956 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results